Videos

A panel of experts review the key drivers contributing to the economic impact of inflammatory diseases in the United States.

Experts discuss the humanistic and economic impacts that affect patients with inflammatory diseases.

Maia Kayal, MD, MS, and Jonathan Kay, MD, provide a clinical overview of inflammatory diseases and describe comorbid conditions typically seen in patients.

Here are the top 5 biosimilar articles for the week of July 10, 2023.

Prerakkumar Parikh, PharmD, and Sneha Sharma, PharmD, from Magellan Rx Management, tackle some of the biggest concerns ophthalmologists have regarding emerging biosimilars for ophthalmic conditions, including interchangeability as well as lack of real-world evidence and education.

Here are the top 5 biosimilar articles for the week of July 3, 2023.

Here are the top 5 biosimilar articles for the week of June 26, 2023.

Juliana (Julie) Reed, executive director of the Biosimilars Forum, predicts how long it will take for savings from adalimumab and ranibizumab biosimilar competition to fully manifest and how stakeholders can champion for better market competition for biosimilars.

Here are the top 5 biosimilar articles for the week of June 19, 2023.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how specialty pharmacists manage inventory, storage, and handling of biosimilars.

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how oncology practices can work better with payers to increase biosimilar adoption and how those collaborations can be applied to other disease areas, such as immunology and neurology.

Here are the top 5 biosimilar articles for the week of June 12, 2023.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses the importance of collaboration between all stakeholders to boost confidence in providing patients with a biosimilar drug.

Here are the top 5 biosimilar articles for the week of June 5, 2023.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what the future biosimilars marketplace may look like compared with generics and reference products at Asembia 2023.

Here are the top 5 biosimilar articles for the week of May 29, 2023.

Here are the top 5 biosimilar articles for the week of May 22, 2023.

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses how the use of biosimilars in other countries strengthens the acceptance and approval of these products in the United States.

Here are the top 5 biosimilar articles for the week of May 15, 2023.

Here are the top 5 biosimilar articles for the week of May 8, 2023.

Andre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, explains how oncologists can work with other stakeholders to expand access to biosimilars and how patients can work with providers and biosimilar manufacturers to address financial challenges.

Here are the top 5 biosimilar articles for the week of May 1, 2023.

Here are the top 5 biosimilar articles for the week of April 24, 2023.

Andre Harvin, PharmD, executive director of pharmacy and oncology services at Cone Health, expressed staunch belief that biosimilars referencing Neulasta Onpro, the on-body injector version of reference pegfilgrastim, are one of the most exciting things coming to the supportive cancer care space.

Here are the top 5 biosimilar articles for the week of April 17, 2023.

Here are the top 5 biosimilar articles for the week of April 10, 2023.

Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM), Christine Baeder discussed what she believes the future holds for biosimilars, good and bad, and the questions that still surround the insulin price cap.

Here are the top 5 biosimilar articles for the week of April 3, 2023.

Here are the top 5 biosimilar articles for the week of March 27, 2023.

Upon coming into her position as the new chair of the Association for Accessible Medicines (AAM) as well as chief operating officer for US generics and biosimilars at Teva Pharmaceuticals USA, Christine Baeder discusses her primary goals in this position, and the challenges that accompany them.